CA3116892A1 - 9(11)-unsaturated neuroactive steroids and their methods of use - Google Patents
9(11)-unsaturated neuroactive steroids and their methods of use Download PDFInfo
- Publication number
- CA3116892A1 CA3116892A1 CA3116892A CA3116892A CA3116892A1 CA 3116892 A1 CA3116892 A1 CA 3116892A1 CA 3116892 A CA3116892 A CA 3116892A CA 3116892 A CA3116892 A CA 3116892A CA 3116892 A1 CA3116892 A1 CA 3116892A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- unsubstituted
- compound
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0007—Androstane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748016P | 2018-10-19 | 2018-10-19 | |
| US62/748,016 | 2018-10-19 | ||
| PCT/US2019/057195 WO2020082065A1 (en) | 2018-10-19 | 2019-10-21 | 9(11)-unsaturated neuroactive steroids and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3116892A1 true CA3116892A1 (en) | 2020-04-23 |
Family
ID=68468867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3116892A Pending CA3116892A1 (en) | 2018-10-19 | 2019-10-21 | 9(11)-unsaturated neuroactive steroids and their methods of use |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210363175A1 (https=) |
| EP (2) | EP3867261B1 (https=) |
| JP (2) | JP7534291B2 (https=) |
| CN (1) | CN113227114B (https=) |
| AR (1) | AR116771A1 (https=) |
| AU (2) | AU2019359899B2 (https=) |
| BR (1) | BR112021007401A2 (https=) |
| CA (1) | CA3116892A1 (https=) |
| DK (1) | DK3867261T3 (https=) |
| ES (1) | ES3039267T3 (https=) |
| MX (2) | MX2021004452A (https=) |
| TW (1) | TW202027754A (https=) |
| WO (1) | WO2020082065A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| DE2526373C2 (de) * | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| JP2545522B2 (ja) * | 1985-10-23 | 1996-10-23 | アルコン・ラボラトーリーズ，インコーポレイテッド | テトラヒドロ脈管形成抑制ステロイド |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US10577390B2 (en) * | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| MA45599A (fr) * | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
-
2019
- 2019-10-21 CA CA3116892A patent/CA3116892A1/en active Pending
- 2019-10-21 EP EP19798489.1A patent/EP3867261B1/en active Active
- 2019-10-21 ES ES19798489T patent/ES3039267T3/es active Active
- 2019-10-21 MX MX2021004452A patent/MX2021004452A/es unknown
- 2019-10-21 JP JP2021521085A patent/JP7534291B2/ja active Active
- 2019-10-21 TW TW108137951A patent/TW202027754A/zh unknown
- 2019-10-21 DK DK19798489.1T patent/DK3867261T3/da active
- 2019-10-21 US US17/286,524 patent/US20210363175A1/en not_active Abandoned
- 2019-10-21 WO PCT/US2019/057195 patent/WO2020082065A1/en not_active Ceased
- 2019-10-21 CN CN201980083218.9A patent/CN113227114B/zh active Active
- 2019-10-21 EP EP25172672.5A patent/EP4606812A3/en active Pending
- 2019-10-21 AR ARP190102988A patent/AR116771A1/es unknown
- 2019-10-21 AU AU2019359899A patent/AU2019359899B2/en active Active
- 2019-10-21 BR BR112021007401-5A patent/BR112021007401A2/pt unknown
-
2021
- 2021-04-16 MX MX2024014845A patent/MX2024014845A/es unknown
-
2024
- 2024-05-07 JP JP2024075254A patent/JP2024096347A/ja active Pending
- 2024-09-30 AU AU2024220209A patent/AU2024220209A1/en active Pending
- 2024-11-07 US US18/940,062 patent/US20250136638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021007401A2 (pt) | 2021-08-03 |
| AU2024220209A1 (en) | 2024-10-17 |
| US20210363175A1 (en) | 2021-11-25 |
| EP3867261A1 (en) | 2021-08-25 |
| EP3867261B1 (en) | 2025-04-30 |
| TW202027754A (zh) | 2020-08-01 |
| EP4606812A2 (en) | 2025-08-27 |
| JP7534291B2 (ja) | 2024-08-14 |
| JP2022505146A (ja) | 2022-01-14 |
| US20250136638A1 (en) | 2025-05-01 |
| AU2019359899B2 (en) | 2024-07-04 |
| ES3039267T3 (en) | 2025-10-20 |
| WO2020082065A1 (en) | 2020-04-23 |
| CN113227114A (zh) | 2021-08-06 |
| MX2021004452A (es) | 2021-08-11 |
| AR116771A1 (es) | 2021-06-09 |
| AU2019359899A1 (en) | 2021-05-20 |
| CN113227114B (zh) | 2026-01-27 |
| EP4606812A3 (en) | 2025-10-15 |
| MX2024014845A (es) | 2025-01-09 |
| JP2024096347A (ja) | 2024-07-12 |
| DK3867261T3 (da) | 2025-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11993628B2 (en) | C7, C12, and C16 substituted neuroactive steroids and their methods of use | |
| JP2024114787A (ja) | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 | |
| AU2019359899B2 (en) | 9(11)-unsaturated neuroactive steroids and their methods of use | |
| WO2021188778A2 (en) | Neuroactive steroids and their methods of use | |
| AU2025200422A1 (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders | |
| HK40130819A (en) | 9(11)-unsaturated neuroactive steroids and their methods of use | |
| HK40106568A (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
| HK40059498A (en) | 9(11)-unsaturated neuroactive steroids and their methods of use | |
| HK40059498B (en) | 9(11)-unsaturated neuroactive steroids and their methods of use | |
| HK40114654A (en) | C7, c12, and c16 substituted neuroactive steroids and their methods of use | |
| HK40105117A (en) | C17, c20, and c21 substituted neuroactive steroids and their methods of use | |
| HK40059417A (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
| HK40059417B (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
| HK40000512B (en) | C17, c20, and c21 substituted neuroactive steroids and their methods of use | |
| HK40000512A (en) | C17, c20, and c21 substituted neuroactive steroids and their methods of use | |
| HK40008786B (en) | C7, c12, and c16 substituted neuroactive steroids and their methods of use | |
| HK40008786A (en) | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241004 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241011 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241011 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241011 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241104 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250328 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250922 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250922 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260121 |